Advancing Science. Improving Connections.
Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare conditions
Pioneering cannabinoid treatments for neuropsychiatric conditions
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINERead More
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsRead More
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023Read More
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumRead More